GP · pain-management
Chronic non-cancer pain and opioid stewardship
Also known as Chronic pain · Opioid prescribing · Opioid tapering
GP-fellowship guide to chronic non-cancer pain and opioid stewardship: functional-goal assessment with yellow flags, non-drug foundations, the medication ladder's honest evidence, opioid initiation criteria, quantified opioid risks, tapering evidence and its harms, opioid use disorder recognition with buprenorphine transition, naloxone co-prescribing and monitoring agreements.
Checked against its sources on 6 Sept 2026
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Opioid dose above 50 morphine milligram equivalents per day with sedation, confusion, or new sleep apnoea — overdose risk territory; reduce and review today
- Benzodiazepine co-prescribed with any opioid — the combination drives overdose; separate them deliberately
- Escalating doses with lost function, early refills, or prescriptions from multiple doctors — screen for opioid use disorder rather than writing more
- Abrupt opioid cessation or forced rapid taper — withdrawal, uncontrolled pain and overdose risk on relapse; taper slowly with support
Overview
Chronic non-cancer pain is pain beyond three months that has outlived its cause. The treatment goal is function — sleep, work, movement — not a pain score of zero. Opioids have a place in cancer pain and end-of-life care; in chronic non-cancer pain the evidence is weak and the harms are dose-related, so stewardship means starting reluctantly, monitoring deliberately, and tapering safely when the harms outrun the benefit.[2]
References8ShowHide
- [1]Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial JAMA, 2018.PMID 29509867
- [2]Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 MMWR Recomm Rep, 2022.PMID 36327391
- [3]Dowell D, Haegerich TM, Chou R CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 MMWR Recomm Rep, 2016.PMID 26987082
- [4]Webster LR, Webster RM Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool Pain Med, 2005.PMID 16336480
- [5]Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis BMJ, 2017.PMID 28292769
- [6]Fenton JJ, Magnan E, Tseregounis IE, et al. Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering JAMA Netw Open, 2022.PMID 35696163
- [7]Larochelle MR, Lodi S, Yan S, et al. Comparative Effectiveness of Opioid Tapering or Abrupt Discontinuation vs No Dosage Change for Opioid Overdose or Suicide for Patients Receiving Stable Long-term Opioid Therapy JAMA Netw Open, 2022.PMID 35960518
- [8]Spreen LA, Dittmar EN, Quirk KC, et al. Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review Pharmacotherapy, 2022.PMID 35302671